Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment

NARecruitingINTERVENTIONAL
Enrollment

566

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2029

Conditions
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
DRUG

APA + ADT

"All participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily. Apalutamide is distributed in Italy under the trade name of Erleada® 60 mg.~All patients not undergoing surgical castration should also continue medical castration by taking a gonadotropin-releasing hormone (GnRHa) analogue during treatment."

PROCEDURE

Local Treatmetn RT or RP

"Patients who will undergo radiotherapy as a local treatment must be treated according to the following scheme:~External beam radiotherapy administered at 36 Gy in six consecutive weekly fractions of 6 Gy, or 55 Gy in 20 daily fractions of 2・75 Gy over 4 weeks.~Radiation therapy will be given with the patient supine and with a full bladder and an empty rectum. The planned target volume is prostate only, with an 8 mm margin posteriorly and a 10 mm margin elsewhere.~No RT on lymph nodes is foreseen. RT should begin 6 months after the first dose of apalutamide (+/- 2 weeks).~Radical prostatectomy should be performed 6 months after the first dose of apalutamide (+/- 2 weeks)."

Trial Locations (3)

20141

NOT_YET_RECRUITING

European Institute of Oncology, Milan

20153

NOT_YET_RECRUITING

ASST Santi Paolo e Carlo, Milan

20156

RECRUITING

Istituto Tumori Milano, Milan

All Listed Sponsors
collaborator

ASST Santi Paolo e Carlo

OTHER

collaborator

European Institute of Oncology

OTHER

lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER